EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 374 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,425,393 | +4.7% | 111,002 | -8.5% | 0.00% | 0.0% |
| Q2 2023 | $2,317,298 | -91.5% | 121,261 | -91.4% | 0.00% | -91.7% |
| Q1 2023 | $27,219,983 | +21.1% | 1,402,369 | +0.1% | 0.05% | +9.1% |
| Q4 2022 | $22,469,057 | -9.4% | 1,400,814 | -11.4% | 0.04% | -12.0% |
| Q3 2022 | $24,789,000 | -21.4% | 1,580,925 | +4.3% | 0.05% | +66.7% |
| Q2 2022 | $31,557,000 | +11.7% | 1,515,712 | +21.6% | 0.03% | +42.9% |
| Q1 2022 | $28,249,000 | +37.9% | 1,246,076 | +11.2% | 0.02% | +50.0% |
| Q4 2021 | $20,488,000 | -13.1% | 1,120,773 | +0.5% | 0.01% | -22.2% |
| Q3 2021 | $23,564,000 | +223.9% | 1,114,673 | +179.2% | 0.02% | +200.0% |
| Q2 2021 | $7,275,000 | +640.8% | 399,300 | +894.8% | 0.01% | +500.0% |
| Q3 2020 | $982,000 | -66.6% | 40,140 | -67.6% | 0.00% | -66.7% |
| Q2 2020 | $2,941,000 | +173.1% | 123,866 | +97.9% | 0.00% | +200.0% |
| Q1 2020 | $1,077,000 | +18.0% | 62,580 | +20.8% | 0.00% | 0.0% |
| Q4 2019 | $913,000 | +187.1% | 51,802 | +188.3% | 0.00% | – |
| Q3 2019 | $318,000 | -69.7% | 17,969 | -63.4% | 0.00% | -100.0% |
| Q2 2019 | $1,048,000 | -71.9% | 49,041 | -68.7% | 0.00% | -75.0% |
| Q1 2019 | $3,728,000 | +17.2% | 156,611 | -3.6% | 0.00% | +33.3% |
| Q4 2018 | $3,182,000 | -50.5% | 162,414 | -55.2% | 0.00% | -50.0% |
| Q3 2018 | $6,422,000 | -63.9% | 362,380 | -56.2% | 0.01% | -64.7% |
| Q2 2018 | $17,810,000 | -28.2% | 827,592 | -26.1% | 0.02% | -29.2% |
| Q1 2018 | $24,821,000 | -28.7% | 1,120,616 | -2.2% | 0.02% | -14.3% |
| Q4 2017 | $34,823,000 | +19.9% | 1,145,466 | -4.5% | 0.03% | +12.0% |
| Q3 2017 | $29,048,000 | -7.9% | 1,198,849 | -6.4% | 0.02% | -19.4% |
| Q2 2017 | $31,540,000 | +41.9% | 1,280,254 | +24.2% | 0.03% | +40.9% |
| Q1 2017 | $22,222,000 | +36.5% | 1,030,992 | -5.5% | 0.02% | +46.7% |
| Q4 2016 | $16,274,000 | +56.5% | 1,091,543 | +30.2% | 0.02% | +50.0% |
| Q3 2016 | $10,397,000 | +22.9% | 838,420 | -22.6% | 0.01% | +11.1% |
| Q2 2016 | $8,461,000 | +1978.9% | 1,083,330 | +802.8% | 0.01% | +800.0% |
| Q2 2014 | $407,000 | -4.2% | 120,000 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $425,000 | -48.7% | 120,000 | -11.1% | 0.00% | 0.0% |
| Q4 2013 | $828,000 | +5.3% | 135,000 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $786,000 | -62.6% | 135,000 | -70.8% | 0.00% | -66.7% |
| Q2 2013 | $2,100,000 | – | 462,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |